Biodexa Pharmaceuticals PLC
BDRX2.270USD
-0.030-1.30%
收盘 12/31, 16:00（美东）报价延迟15分钟
14.06B总市值
13.02市盈率 TTM
关于 Biodexa Pharmaceuticals PLC 公司
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Biodexa Pharmaceuticals PLC简介
公司代码BDRX
公司名称Biodexa Pharmaceuticals PLC
上市日期Dec 08, 2014
CEOStamp (Stephen A)
员工数量- -
证券类型Depository Receipt
年结日Dec 08
公司地址1 Caspian Point
城市ABINGDON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United Kingdom
邮编CF10 4DQ
电话4401235888300
网址https://www.biodexapharma.com/
公司代码BDRX
上市日期Dec 08, 2014
CEOStamp (Stephen A)
Biodexa Pharmaceuticals PLC公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
Mr. Dmitry Zamoryakhin, M.D.
Mr. Dmitry Zamoryakhin, M.D.
Chief Scientific Officer, Chief Medical Officer
Chief Scientific Officer, Chief Medical Officer
--
--
Ms. Nicola Tuckwell
Ms. Nicola Tuckwell
Vice President, Head of Clinical Operations
Vice President, Head of Clinical Operations
--
--
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Simon Turton
Dr. Simon Turton
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Daniel (Dan) Palmer, Ph.D.
Dr. Daniel (Dan) Palmer, Ph.D.
Vice President - Technology
Vice President - Technology
--
--
Mr. Stephen A. Stamp
Mr. Stephen A. Stamp
Chief Executive Officer, Chief Financial Officer, Executive Director
Chief Executive Officer, Chief Financial Officer, Executive Director
--
--
Dr. Stephen Barry Parker
Dr. Stephen Barry Parker
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Ms. Fiona Sharp
Ms. Fiona Sharp
Group Financial Controller
Group Financial Controller
--
--
Dr. Gary A. Shangold, M.D.
Dr. Gary A. Shangold, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Steve Ellul
Mr. Steve Ellul
Chief Business Officer
Chief Business Officer
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
由于公司未披露，未能获取相关数据
地区USD
名称
营收
占比
Belgium
381.00K
100.00%
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月29日 周六
更新时间: 11月29日 周六
持股股东
股东类型
持股股东
持股股东
占比
Brio Capital Management LLC
2.71%
UBS Switzerland AG
1.12%
Abbe (Richard)
0.39%
Bukwang Pharmaceutical Co., Ltd.
0.23%
Melior Pharmaceuticals I, Inc.
0.23%
其他
95.32%
持股股东
持股股东
占比
Brio Capital Management LLC
2.71%
UBS Switzerland AG
1.12%
Abbe (Richard)
0.39%
Bukwang Pharmaceutical Co., Ltd.
0.23%
Melior Pharmaceuticals I, Inc.
0.23%
其他
95.32%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
2.92%
Bank and Trust
1.12%
Corporation
0.56%
Individual Investor
0.39%
Investment Advisor
0.23%
Hedge Fund
0.07%
Research Firm
0.02%
其他
94.69%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
25
26.99K
4.36%
-3.65K
2025Q3
27
27.63K
4.95%
+6.43K
2025Q2
30
21.20K
5.92%
-17.70K
2025Q1
32
21.37K
16.41%
+10.40K
2024Q4
31
19.96K
16.99%
+9.20K
2024Q3
33
10.76K
4.86%
+5.02K
2024Q2
29
4.42K
2.68%
+1.32K
2024Q1
25
3.10K
2.07%
+2.75K
2023Q4
26
3.28K
0.82%
+3.22K
2023Q3
18
57.00
107.67%
+15.00
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Brio Capital Management LLC
16.77K
2.71%
+11.06K
+193.61%
Nov 14, 2024
UBS Switzerland AG
6.92K
1.12%
+6.73K
+3379.90%
Sep 30, 2025
Abbe (Richard)
2.43K
0.39%
+2.43K
--
Jul 19, 2024
Bukwang Pharmaceutical Co., Ltd.
1.42K
0.23%
+1.42K
--
Apr 01, 2024
Melior Pharmaceuticals I, Inc.
1.42K
0.23%
+1.42K
--
Apr 01, 2024
Mercer Street Capital Partners, LLC
1.42K
0.23%
+793.00
+126.88%
Apr 01, 2024
GAMMA Investing LLC
1.35K
0.22%
+158.00
+13.23%
Sep 30, 2025
GS Capital Partners LLC
631.00
0.1%
+631.00
--
Apr 01, 2024
District 2 Capital LP
403.00
0.07%
-449.00
-52.70%
Nov 11, 2024
SBI Securities Co., Ltd.
115.00
0.02%
-452.00
-79.72%
Sep 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
公告日期
类型
比率
Jul 15, 2025
Merger
10→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Sep 19, 2024
Merger
25→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Jun 26, 2023
Merger
80→1
Mar 16, 2023
Merger
4→1
查看更多
常见问题
Biodexa Pharmaceuticals PLC的前五大股东是谁？
Biodexa Pharmaceuticals PLC 的前五大股东如下：
Brio Capital Management LLC持有股份：16.77K，占总股份比例：2.71%。
UBS Switzerland AG持有股份：6.92K，占总股份比例：1.12%。
Abbe (Richard)持有股份：2.43K，占总股份比例：0.39%。
Bukwang Pharmaceutical Co., Ltd.持有股份：1.42K，占总股份比例：0.23%。
Melior Pharmaceuticals I, Inc.持有股份：1.42K，占总股份比例：0.23%。
Brio Capital Management LLC持有股份：16.77K，占总股份比例：2.71%。
UBS Switzerland AG持有股份：6.92K，占总股份比例：1.12%。
Abbe (Richard)持有股份：2.43K，占总股份比例：0.39%。
Bukwang Pharmaceutical Co., Ltd.持有股份：1.42K，占总股份比例：0.23%。
Melior Pharmaceuticals I, Inc.持有股份：1.42K，占总股份比例：0.23%。
Biodexa Pharmaceuticals PLC的前三大股东类型是什么？
Biodexa Pharmaceuticals PLC 的前三大股东类型分别是：
Brio Capital Management LLC
UBS Switzerland AG
Abbe (Richard)
Brio Capital Management LLC
UBS Switzerland AG
Abbe (Richard)
有多少机构持有Biodexa Pharmaceuticals PLC(BDRX)的股份？
截至2025Q4，共有25家机构持有Biodexa Pharmaceuticals PLC的股份，合计持有的股份价值约为26.99K，占公司总股份的4.36%。与2025Q3相比，机构持股有所增加，增幅为-0.59%。
哪个业务部门对Biodexa Pharmaceuticals PLC的收入贡献最大？
在FY2023，--业务部门对Biodexa Pharmaceuticals PLC的收入贡献最大，创收--，占总收入的--%。
